This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events TPM0 주식 개요 A biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. 자세한 내용
보상 위험 분석 + 2 더 많은 위험
모든 위험 점검 보기 {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
Tonix Pharmaceuticals Holding Corp. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Tonix Pharmaceuticals Holding 과거 주가 현재 주가 US$2.82 52주 최고치 US$9.84 52주 최저치 US$1.69 베타 2.22 1개월 변경 0% 3개월 변경 사항 -0.79% 1년 변경 사항 -70.98% 3년 변화 -98.58% 5년 변화 -99.99% IPO 이후 변화 -100.00%
최근 뉴스 및 업데이트
Tonix Pharmaceuticals Holding Corp. Announces Promotion of Siobhan Fogarty to Chief Technical Officer Feb 04
Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Dec 24
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application (Nda) for Tnx-102 Sl for Fibromyalgia Dec 18
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Dec 10
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting Nov 19 Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 Nov 02
더 많은 업데이트 보기
Tonix Pharmaceuticals Holding Corp. Announces Promotion of Siobhan Fogarty to Chief Technical Officer Feb 04
Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Dec 24
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application (Nda) for Tnx-102 Sl for Fibromyalgia Dec 18
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Dec 10
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting Nov 19 Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 Nov 02
Tonix Pharmaceuticals Holding Corp Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) Oct 16
Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency Sep 16
Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine Sep 11
Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations Sep 10 Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares. Sep 08
Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium Aug 29
Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium Aug 28
Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication Aug 20 Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency
Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain Aug 13 Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya Aug 01 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million. Jul 31
Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia Jul 26
Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025 Jul 18 Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.041439 million. Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jul 09
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Jul 08 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jun 27
Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024 Jun 26
Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia Jun 21 Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million. Jun 15
Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jun 13
Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 Jun 08
ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting Jun 05
Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024 Apr 16 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million. Mar 29
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting Mar 22
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy Mar 08
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans Mar 06
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers Mar 02
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December Feb 17
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024 Feb 15
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD Feb 14
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia Jan 10 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Dec 22
Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity Dec 04
Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder Nov 14
National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Nov 04
Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder Nov 01
Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs Oct 27
Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Oct 21
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models Oct 19
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder Oct 17
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder Sep 28
Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700 Sep 22
Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine Sep 07
Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID Sep 06
Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox Aug 22
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers Aug 17
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia Aug 02
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder Aug 01
Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023 Jul 27
Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test Jul 25
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity Jul 11 Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million. Jun 27
Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia Jun 16
Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress Jun 08
Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER Jun 06
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement May 26
Tonix Pharmaceuticals Holding Corp. Announces the Discovery Byscientists of the Isomers of Racemic Tianeptine May 25
Tonix Pharmaceuticals Holding Corp. Announces Molecular Mechanism of Action of Tianeptine, the Active Ingredient of the Company's TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) Product Candidate May 18
Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application to Support A Phase 1 Clinical Trial with TNX-1500 May 06
Tonix Pharmaceuticals Holding Corp. Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies Feb 15
Tonix Pharmaceuticals Holding Corp. Announces Publication of Paper in Viruses Highlighting the Company’S Development of A Vaccine to Protect Against Monkeypox and Smallpox (Tnx-801) Feb 10
Tonix Pharmaceuticals Holding Corp. Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs Feb 07
Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) entered into an agreement to acquire All of the assets of Healion Bio, Inc. Feb 03
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Jan 31
Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $12.5 million worth of its shares. Jan 26 주주 수익률 TPM0 DE Biotechs DE 마켓 7D 0% 1.2% 2.3% 1Y -71.0% -5.6% 16.7%
전체 주주 수익률 보기
수익률 대 산업: TPM0 지난 1년 동안 -5.6 %를 반환한 German Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: TPM0 지난 1년 동안 16.7 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is TPM0's price volatile compared to industry and market? TPM0 volatility TPM0 Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
안정적인 주가: TPM0 지난 3개월 동안 German 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: 지난 1년간 TPM0 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
Tonix Pharmaceuticals Holding Corp. 기본 사항 요약 Tonix Pharmaceuticals Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요? TPM0 기본 통계 시가총액 €11.78m 수익(TTM ) -€112.19m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) TPM0 손익 계산서(TTM ) 수익 US$0 수익 비용 US$0 총 이익 US$0 기타 비용 US$123.47m 수익 -US$123.46m
주당 순이익(EPS) -9.29 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 0%
TPM0 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2023/08/06 05:53 장 마감 주가 2023/05/09 00:00 수익 2023/03/31 연간 수익 2022/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Tonix Pharmaceuticals Holding Corp. 10 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 James Molloy Alliance Global Partners David Buck B. Riley Securities, Inc. Kumaraguru Raja Brookline Capital Markets
7 더 많은 분석가 보기 
